How we grade evidence
- L1 Multiple randomized controlled trials with consistent effect; systematic reviews support the intervention.
- L2 At least one RCT plus larger case series; effect direction consistent but magnitude debated.
- L3 Case series, small pilots, animal data extrapolated; plausible but unproven at scale.
- L4 Testimonial, marketing, or fringe-diagnosis claims without peer-reviewed evidence of benefit.
What tendinopathy actually is (and why it heals badly)
Achilles tendinopathy is degeneration, not inflammation — this matters. The term "tendinitis" is a decades-old misnomer; biopsies of chronic Achilles tendon problems show collagen disorganization, mucoid degeneration, and neovascularization rather than active inflammatory cells. That is why NSAIDs help symptoms transiently but do not fix the tissue, and why steroid injections are broadly discouraged (they can weaken tendon structure and predispose to rupture).
Standard first-line therapy — eccentric loading (Alfredson protocol) or heavy slow resistance — resolves symptoms in the majority of patients within 3–6 months. But a subset does not respond, and that is where regenerative options enter the conversation.
What the evidence for cell therapy in tendon looks like
Tendon has one of the stronger evidence bases in regenerative medicine — not overwhelming, but stronger than most other indications. Small randomized trials of skin-derived tenocyte-like cell injections for lateral epicondylitis (tennis elbow) have shown durable pain reduction. For rotator cuff tears, bone-marrow-concentrate augmentation of surgical repair has published RCT data showing improved healing rates. Achilles specifically has fewer trials than elbow but shares the same tendinopathy biology, and case series with bone-marrow-derived MSCs and adipose-derived cells report pain and function improvements sustained at 12–24 months.
The mechanistic story is coherent: tendinopathy is failed healing, and MSCs modulate the environment toward tissue repair rather than differentiating into new tendon themselves. That is a supportable claim.
PRP first, cells second — the honest sequencing
Platelet-rich plasma has more published Achilles data than cell therapy. It is cheaper, autologous by definition, and reasonable to try before escalating. If PRP fails after two or three injections spaced properly, cell therapy is a more defensible next step than jumping straight to it.
Where cell therapy earns its cost
- Insertional Achilles tendinopathy that has failed loading and PRP — the calcaneal insertion is notoriously stubborn.
- Chronic midportion tendinopathy present more than six months, with clear ultrasound or MRI findings of degeneration.
- Partial-thickness tears where surgical intervention would otherwise be the next step.
Where it does not earn its cost: acute Achilles pain of a few weeks' duration in someone who has not yet done a full eccentric loading program. Do the loading first.
What treatment day actually looks like
Ultrasound-guided injection of the cell product into the region of degeneration, sometimes with tendon needling (fenestration) to trigger a healing response. Local anesthesia. Same-day discharge. A brief immobilization period followed by a graduated loading program is standard — the return-to-loading protocol is arguably as important as the injection itself. Clinics that inject and send you home with no rehab protocol are undervaluing the mechanical stimulus half of the therapy.
Weeks 1–4: pain often unchanged or slightly worse (inflammatory response to the injection). Weeks 6–12: usually where noticeable improvement begins. Months 3–6: further gains with continued loading. Anyone promising immediate relief is oversimplifying the biology.
Regulatory status — Achilles tendinopathy
Failed eccentrics and PRP already? Let's talk.
We'll help you assess whether cell therapy is the right next step, and what to ask a clinic.
Ask a question on WhatsApp